{"filing":{"accession_number":"0001048477-26-000015","cik":"0001048477","ticker":"BMRN","company_name":"BIOMARIN PHARMACEUTICAL INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"bmrn-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/bmrn-20260806.htm"},"events":[{"id":25380,"run_id":23029,"accession_number":"0001048477-26-000015","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"BioMarin disclosed second quarter 2026 financial results on August 6, 2026, with total revenues of $990 million (20% YoY increase), GAAP net income of $45 million, and Non-GAAP diluted EPS of $1.20. The company also raised full-year 2026 guidance for Total Revenues, VOXZOGO, and Non-GAAP Diluted EPS, reflecting strong first-half performance. This is a standard quarterly earnings release with material financial metrics and forward guidance, furnished as Exhibit 99.1 per Item 2.02.","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26183,"accession_number":"0001048477-26-000015","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"BioMarin disclosed second quarter 2026 financial results on August 6, 2026, with total revenues of $990 million (20% YoY increase), GAAP net income of $45 million, and Non-GAAP diluted EPS of $1.20. The company also raised full-year 2026 guidance for Total Revenues, VOXZOGO, and Non-GAAP Diluted EPS, reflecting strong first-half performance. This is a standard quarterly earnings release with material financial metrics and forward guidance, furnished as Exhibit 99.1 per Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:36:28.071467+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26183,"accession_number":"0001048477-26-000015","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"BioMarin disclosed second quarter 2026 financial results on August 6, 2026, with total revenues of $990 million (20% YoY increase), GAAP net income of $45 million, and Non-GAAP diluted EPS of $1.20. The company also raised full-year 2026 guidance for Total Revenues, VOXZOGO, and Non-GAAP Diluted EPS, reflecting strong first-half performance. This is a standard quarterly earnings release with material financial metrics and forward guidance, furnished as Exhibit 99.1 per Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:36:28.071467+00:00","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-08-06"}]}